Phase 2 Lymphoma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are 18 years of age or older
• People who are willing and able to sign a consent form for the study
• People who have been diagnosed with Large B-cell Lymphoma confirmed by a tissue sample test
• People whose lymphoma has come back, stopped responding, or gotten worse after receiving at least two rounds of treatment, including a specific type of chemotherapy (anthracyclines), an anti-cancer antibody targeting CD20 (such as rituximab), and a stem cell transplant using their own cells
• People whose lymphoma can be detected and measured using PET and CT scans, according to standard lymphoma assessment guidelines
• People who are in generally good physical condition, able to carry out normal daily activities with little or no limitation (rated 0 or 1 on a standard health scale used in clinical trials)
• People whose heart, liver, kidneys, and other organs are functioning well enough to meet the trial's requirements
• People who have suitable veins or blood vessel access to allow a blood cell collection procedure called leukapheresis
• People who have previously received a treatment targeting CD19, where it has been confirmed that their lymphoma cells still carry the CD19 marker
• Women who could become pregnant must agree to use highly effective contraception for one year after the last dose of the study treatment (Relma-cel)
• Men whose partners could become pregnant must agree to use effective barrier contraception for one year after the last dose of the study treatment (Relma-cel)

Who may not be able to join:

• People whose lymphoma started in the brain or spinal cord (primary CNS lymphoma)
• People who have had another separate cancer that has not been in remission for at least two years
• People who have an active infection with hepatitis B, hepatitis C, HIV, or syphilis at the time of screening
• People who have an active blood clot in a vein or in the lungs, or who have needed blood-thinning medication for a clot within the three months before signing the consent form
• People who have an infection (fungal, bacterial, viral, or other) that is not under control
• People who have a condition called graft-versus-host disease (GVHD), either current or ongoing, which can occur after certain types of transplants
• People with a history of serious heart disease or significant brain or nervous system conditions
• People who are pregnant or currently breastfeeding
• People who have recently received certain other treatments for lymphoma — including chemotherapy, steroids, experimental drugs, radiation, or a donor stem cell transplant — and have not waited long enough since their last dose (confirm with trial site for specific timeframes)
• People who are unable or unwilling to follow the procedures and requirements set out in the study plan
• People who have previously received CAR T-cell therapy or any other type of genetically modified T-cell therapy

Important: Always verify eligibility with the trial site directly before applying.